comparemela.com

Latest Breaking News On - Dr mathew garnett translational cancer genomics laboratory - Page 1 : comparemela.com

Mosaic Therapeutics Closes $28m Series A Funding and Appoints Brian Gladsden as CEO

Company developing targeted oncology therapies spun out of world-leading research at the Wellcome Sanger Institute, in collaboration with the Netherlands Cancer Institute Syncona and Cambridge

South koreaUnited kingdomMathew garnettBrian gladsdenEmile voestAnne horganMagdalena jonikasKatie odgaardAdrian ibrahimBayer agLoncode instituteDr mathew garnett translational cancer genomics laboratorySyncona investment management ltdSenior group leader at sangerGroup leaderHead of technology translation

Syncona : Mosaic Therapeutics closes $28m series A funding and appoints Brian Gladsden as CEO

Company developing targeted oncology therapies spun out of world-leading research at the Wellcome Sanger Institute, in collaboration with the Netherlands Cancer Institute . | April 4, 2023

United kingdomSouth koreaEmile voestMagdalena jonikasAnne horganMathew garnettKatie odgaardAdrian ibrahimBrian gladsdenInternational cancer genome consortiumSyncona investment management ltdWorldwide leadership teamZyme communicationsBayer agMosaic therapeutics ltdGroup leader

Mosaic Therapeutics Closes $28M Series A Funding

FinSMEs is the financial news site dedicated to covering venture capital, private equity, and merger and acquisition deals in real time!

United kingdomEmile voestAdrian ibrahimBrian gladsdenHead of technology translationSenior group leader at sangerNetherlands cancer instituteGroup leaderLoncode instituteDr mathew garnett translational cancer genomics laboratoryWellcome sanger instituteMosaic therapeuticsUnited kingdom basedSyncona investment managementCambridge innovationNovartis oncology

Mosaic Therapeutics closes $28m series A funding and appoints Brian Gladsden as CEO

Company developing targeted oncology therapies spun out of world-leading research at the Wellcome Sanger Institute, in collaboration with the Netherlands Cancer Institute Syncona and Cambridge Innovation Capital invested Former Novartis SVP appointed as CEO to drive growth ambitions Mosaic Therapeuti

United kingdomSouth koreaMagdalena jonikasAdrian ibrahimEmile voestBrian gladsdenMathew garnettPartner at syncona investment managementSyncona investment management ltdMosaic therapeutics ltdNetherlands cancer instituteWorldwide leadership teamHead of technology translationBayer agDr mathew garnett translational cancer genomics laboratoryLoncode institute

vimarsana © 2020. All Rights Reserved.